Bajaj Healthcare Limited has informed the Exchange regarding 'Financial Results for the Quarter ended 30th June 2025'.
BAJAJHCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.0 pts less than Nifty Microcap 250 and 3.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bajaj Healthcare reported Q1 FY26 revenue from operations of Rs. 14,883.63 lakhs, up about 12.5% from Rs. 13,224.67 lakhs in Q1 FY25. Profit before tax from continuing operations jumped to Rs. 1,452.51 lakhs (vs Rs. 1,018.41 lakhs, ~42.6% growth), and profit after tax from continuing operations rose ~51.7% to Rs. 1,217.37 lakhs. Total profit for the period (including discontinued operations) was Rs. 1,183.37 lakhs versus Rs. 713.19 lakhs, with basic EPS at Rs. 3.74 (vs Rs. 2.59). The auditor (Walker Chandiok & Co LLP) issued an unmodified review report. The company also disclosed the April 2025 acquisition of Genrx Pharmaceuticals (on a going concern basis for Rs. 1,085 lakhs) and progress on its September 2024 preferential issue, where Rs. 15,225.90 lakhs has been utilised, mainly for loan repayment.
Strong bottom-line growth driven by lower finance costs and improved operating leverage is positive for shareholders, though topline growth was modest. The Genrx acquisition and ongoing preferential issue proceeds point to expansion and deleveraging efforts, which could support future earnings.